Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT07011485

A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.

A Triple-Blind, Randomized, Efficacy and Tolerability Comparison Study of PDFE-2304 Topical Solution Versus Minoxidil 5% Topical Solution for the Treatment of Androgenic Alopecia (AGA).

Status
Active Not Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
15 (estimated)
Sponsor
PDFE Pharma Innovations FZCO · Industry
Sex
Male
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate the safety and efficacy of PDFE-2304 compared with Minoxidil 5% in men with androgenic alopecia (AGA).

Conditions

Interventions

TypeNameDescription
DRUGMinoxidil 5% Topical SolutionApproximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.
DRUGPDFE-2304 Topical SolutionApproximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.

Timeline

Start date
2025-05-14
Primary completion
2025-08-14
Completion
2025-09-17
First posted
2025-06-08
Last updated
2025-06-08

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT07011485. Inclusion in this directory is not an endorsement.

A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia. (NCT07011485) · Clinical Trials Directory